Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Piyan Zhang
Observed name:
Zhang Piyan
Observed institutions:
Beth Israel Deaconess Medical Center,
Mayo Clinic,
Harvard University,
Thomas Jefferson University,
Thomas Jefferson University Hospital,
Sidney Kimmel Cancer Center
show all 6
ORCID:
0000-0002-2419-4837
Observed ORCID:
0000-0002-2419-4837
OpenAlex ID:
A5085932053
The Ku-dependent non-homologous end-joining but not other repair pathway is inhibited by high linear energy transfer ionizing radiation
2008
·
Hongyan Wang
, Xiang Wang
, et al.
·
DNA repair
·
119
Targeting HER 2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy
2018
·
Faye R. Harris
, Piyan Zhang
, et al.
·
Molecular Oncology
·
34
PDF
S-Phase Cells Are More Sensitive to High-Linear Energy Transfer Radiation
2009
·
Hongyan Wang
, Shuang Liu
, et al.
·
International Journal of Radiation Oncology*Biology*Physics
·
34
Agrobacterium tumefaciens-mediated transformation as a tool for insertional mutagenesis in the fungus Penicillium marneffei
2008
·
Piyan Zhang
, Bin Xu
, et al.
·
Mycological Research
·
34
Overlooked FANCD2 variant encodes a promising, portent tumor suppressor, and alternative polyadenylation contributes to its expression
2017
·
Bing Han
, Yihang Shen
, et al.
·
Oncotarget
·
30
PDF
FAVL impairment of the Fanconi anemia pathway promotes the development of human bladder cancer
2012
·
Jayabal Panneerselvam
, Hwan Ki Park
, et al.
·
Cell Cycle
·
27
Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancer
2021
·
Tommaso Grassi
, Faye R. Harris
, et al.
·
PLoS ONE
·
26
PDF
Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
2023
·
Alan T. Yeo
, Rushil Shah
, et al.
·
Cancer Immunology Research
·
22
PDF
EGFRvIII tumorigenicity requires PDGFRA co-signaling and reveals therapeutic vulnerabilities in glioblastoma
2021
·
Alan T. Yeo
, Hyun Jung Jun
, et al.
·
Oncogene
·
22
Heterogeneity of Extracellular Vesicles and Non‐Vesicular Nanoparticles in Glioblastoma
2025
·
Tuoye Xu
, Joao A. Paulo
, et al.
·
Journal of Extracellular Vesicles
·
9
PDF
Frequently rearranged and overexpressed δ-catenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and β-catenin antagonists
2018
·
Piyan Zhang
, Janet Schaefer-Klein
, et al.
·
Oncotarget
·
7
PDF
The EV antibody database: An interactive database of curated antibodies for extracellular vesicle and nanoparticle research
2024
·
Amber Morey
, Martin Ng
, et al.
·
Extracellular Vesicle
·
5
Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
2023
·
Alan T. Yeo
, Rushil Shah
, et al.
·
3
RAPD analysis technique and it^s application to the studies on the animal genetics and breeding
2000
·
Piyan Zhang
, Zhuang Xie
, et al.
·
Progress in biotechnology
·
1
Nonclinical development of advanced therapies: Best practices for translational and regulatory success
2026
·
Piyan Zhang
·
Regulatory Toxicology and Pharmacology
Supplementary Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
2025
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data Table1 from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
2025
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data Table 2 from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
2025
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data Table1 from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
2024
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data Table 2 from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
2024
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data Table 2 from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
2024
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data Table1 from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
2024
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
2024
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data from Driver mutations dictate the immunological landscape and response to checkpoint immunotherapy of glioblastoma
2024
·
Alan T. Yeo
, Rushil Shah
, et al.
Supplementary Data from Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
2023
·
Alan T. Yeo
, Rushil Shah
, et al.
Show more works
View as search
Works count:
45
Citation count:
372
H-index:
9
I10-index:
9
Year
Topic
Type